Ladenburg Thalmann Downgrades Cempra, Inc. (CEMP) to Neutral

Cempra (CEMP) Sees 21% 'Dead Cat Bounce'

After plunging 57% on Thursday, Cempra (NASDAQ: CEMP) is making a fierce comeback today. Shares are up 21.2% today to $3.15, helped in part by an upgrade to Equalweight at Morgan Stanley. Morgan Stanley was negative into yesterday plunge on the back of ab FDA CRL for Solithromycin.

Morgan Stanley Upgrades Cempra, Inc. (CEMP) to Equalweight

Morgan Stanley upgraded Cempra, Inc. (NASDAQ: CEMP) from Underweight to Equalweight with a price target of $3.00 (from $5.00) after the FDA issued a CRL on Solithera and the related 57.6% sell-off.

For an analyst ratings summary and ratings history on Cempra, Inc.... More

WBB Securities Downgrades Cempra, Inc. (CEMP) to Hold

WBB Securities downgraded Cempra, Inc. (NASDAQ: CEMP) from Strong Buy to Hold with a price target of $4.00 (from $40.00) following today's CRL.

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Meaningful Commercial role for Cempra's (CEMP) Solithera 'Unlikely' - Needham & Company

Needham & Company analyst Alan Carr reiterated a Hold rating on Cempra, Inc. (NASDAQ: CEMP) after the FDA issued a CRL on Solithera.

Carr commented, "The agency reportedly informed company that safety profile of Solithera has not been adequately characterized and a larger safety... More

Cempra (CEMP) PT Slashed to $2 at Baird Amid CRL

Baird analyst Brian Skorney reiterated an Underperform rating and slashed his price target on Cempra, Inc. (NASDAQ: CEMP) to $2.00 (from $6.00) following the FDA CRL.

Skorney commented, "With back-to-back PDUFA dates of the 27th/28th for oral/IV formulations of solithromycin, Cempra finally... More

Cempra (CEMP) Sinks 14% Following FDA CRL on Solithromycin

Cempra, Inc. (Nasdaq: CEMP) is down 13.9% in pre-open trade Thursday after the company announced that it has received a Complete Response Letter... More

Cempra (CEMP) Receives FDA CRL for Solithromycin NDAs

Cempra (Nasdaq: CEMP) announced that the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) relating to the companys new drug applications (NDAs) for oral and intravenous solithromycin for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

The CRL states that the FDA cannot approve the NDAs in their present form and notes that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies are required before the NDAs may be... More